BC Week In Review | Jul 3, 2000
Clinical News

CTL102/CB1954 gene therapy: Began Phase I/II testing

ML Laboratories plc (LSE:MLB), Liverpool, U.K.   Product: CTL102/CB1954 gene therapy   Business: Cancer   Therapeutic category: Gene therapy, Cytotoxic   Target: CB1954 monofunctional alkylating agent   Description: Gene Directed Enzyme Prodrug Therapy (GDEPT) that...
BC Week In Review | Jun 26, 2000
Clinical News

CTL102/CB1954: Began Phase I/II trial

ML Laboratories plc (LSE:MLB), Liverpool, U.K.   Product: CTL102/CB1954   Business: Gene/Cell therapy, Cancer   Therapeutic category: Gene therapy   Target: Cancer cells   Description: Intratumoral injection of gene encoding an enzyme that converts the...
Items per page:
1 - 2 of 2